Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Antibody Test Validates Diagnosis of Heparin-Induced Thrombocytopenia

By LabMedica International staff writers
Posted on 23 Sep 2010
An immunoassay has been validated as diagnostic for heparin-induced thrombocytopenia (HIT), the most important and most frequent drug-induced, immune-mediated type of platelet deficiency.

The enzyme-linked immunosorbent assay (ELISA) detects antibodies in the blood to the heparin/platelet factor 4 (PF4) complexes. It is now known that antibodies associated with Type II HIT recognize sites on "platelet factor 4” (PF4) that are created when PF4 is complexed with heparin or another linear polyanionic compound such as polyvinyl sulfonate (PVS).

The PF4 Enhanced Solid Phase ELISA is manufactured by GTI diagnostics, (Waukesha, WI, USA), who recommends the use of a high-dose heparin confirmatory procedure to improve the specificity of the ELISA. In this particular assay, inhibition of a positive ELISA result by 50% or more in the presence of excess heparin (100 U/mL) is considered confirmatory of heparin-dependent antibodies.

In a retrospective study carried out at the Duke University Medical Center (Durham, NC, USA), 115 patients with anti-heparin/PF4 antibodies, detected by the ELISA, were classified as clinically HIT-positive or HIT-negative, followed by confirmation with excess heparin. Heparin-induced thrombocytopenia, was defined as at least a 30% decline in the platelet count, with a platelet count increase after heparin cessation; timing of platelet counts fall between 4 and 14 days after heparin exposure or within 24 to 48 hours if heparin exposures was recent (within the last 100 days); and lack of other, predominant causes of thrombocytopenia. A multivariate logistic regression model was fitted to estimate relationships between patient characteristics, laboratory findings, and clinical HIT status. This model was validated on an independent sample of 97 patients with anti-heparin/PF4 antibodies.

The optical density (OD) value of anti-heparin/PF4 antibodies detected by ELISA correlated with both a clinical diagnosis of HIT and a higher incidence of heparin-induced thrombocytopenia and thrombosis (HITT).

The authors of the study concluded that the confirmatory assay with excess heparin is a valuable adjunct in the laboratory diagnosis of HIT. With a multivariate statistical model, the probability of being clinically HIT positive can be estimated for an individual patient with both the maximal anti-heparin/PF4 OD value and the confirmatory assay result. Accurate predictions of the probabilities of HIT will enable clinicians to initiate appropriate therapy rapidly, thereby reducing complications of HIT. The results of the study were published in the September 2010 issue of the journal Blood.

Related Links:

GTI diagnostics
Duke University Medical Center



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
TORCH Infections Test
TORCH Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.